TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21382516

Group type: EXPERIMENTAL
Intervention: Community Care (CC) - 6 month SDT-based intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended Need Support (ENS) - 12 month SDT-based intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Harm Reduction (HR) - Extended need support with medication recommendation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary outcome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 0
Study: 18974068

Group type: EXPERIMENTAL
Intervention: Activator-headgear appliance for at least 9 months followed by fixed appliance therapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Minor orthodontic treatment (control group)
Number of subjects: 64
Study: 16724576

Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil plus 0.5 g/kg ethanol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ethanol plus placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vardenafil plus placebo
Number of subjects: 12
Study: 14606098

Group type: EXPERIMENTAL
Intervention: High-dose Vitamin C (10 g/day) intravenously for 5 days
Number of subjects: 84

Group type: COMPARATOR
Intervention: Low-dose Vitamin C (1 g/day) intravenously for 5 days
Number of subjects: 84
Study: 10779882

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study: 2024983

Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin for 24 weeks
Number of subjects: 251

Group type: COMPARATOR
Intervention: Vehicle-treated control
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin therapy
Number of subjects: 251
Study: 6941460

Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 43

Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 43
Study: 31056218

Group type: COMPARATOR
Intervention: Drug (exact dosage and duration not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28319853

Group type: EXPERIMENTAL
Intervention: High-fat meal challenge (500/1000/1500 kcal)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-fat meal challenge (1500 kcal)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High-fat meal challenge
Number of subjects: 14
Study: 27098321

Group type: EXPERIMENTAL
Intervention: Robotic-assisted unicompartmental knee arthroplasty
Number of subjects: 139

Group type: COMPARATOR
Intervention: Conventional unicompartmental knee arthroplasty
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Robotic-assisted femoral component sagittal position
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Robotic-assisted femoral component coronal position
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Robotic-assisted femoral component axial position
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Robotic-assisted tibial component sagittal position
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Robotic-assisted tibial component axial position
Number of subjects: 139
Study: 25041339

Group type: EXPERIMENTAL
Intervention: basiliximab + belatacept high dose (HD) + mycophenolate mofetil (MMF)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: belatacept HD + MMF
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: belatacept low dose (LD) + MMF
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: tacrolimus + MMF
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: tacrolimus alone
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: belatacept (all groups)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: belatacept HD
Number of subjects: 260

Group type: COMPARATOR
Intervention: basiliximab + belatacept HD
Number of subjects: 260

Group type: COMPARATOR
Intervention: tacrolimus
Number of subjects: 260
Study: 22297244

Group type: EXPERIMENTAL
Intervention: Everolimus 10mg once daily (n=277)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Placebo (n=139)
Number of subjects: 416
Study: 20206844

Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microg/kg
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg/kg
Number of subjects: 160
Study: 17372025

Group type: EXPERIMENTAL
Intervention: Grass pollen immunotherapy (Phleum pratense)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Post-IT IgA fractions
Number of subjects: 44
Study: 16279148

Group type: EXPERIMENTAL
Intervention: Pravastatin (specific dosage and duration not mentioned)
Number of subjects: 2520

Group type: EXPERIMENTAL
Intervention: Summary of study results sent to primary care physicians
Number of subjects: 2520
Study: 11897644

Group type: EXPERIMENTAL
Intervention: Partial liquid ventilation (PLV) with perflubron
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Partial liquid ventilation (PLV)
Number of subjects: 90
Study: 10206118

Group type: EXPERIMENTAL
Intervention: MDT + 10 daily doses of 2 x 10(6) IU of recombinant human IFN-gamma/m2 followed by 10 daily doses of 10(7) IU IFN-gamma/m2
Number of subjects: 20

Group type: COMPARATOR
Intervention: MDT alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MDT + IFN-gamma
Number of subjects: 20
Study: 7540413

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody B724
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control ELISAs using polyclonal antibodies
Number of subjects: 0
Study: 2230890

Group type: EXPERIMENTAL
Intervention: Preoperative intraarterial cisplatin (CDP) and surgery (TIOS I and III)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Chemotherapy only (TIOS II)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Amputation
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Limb salvage
Number of subjects: 98

Group type: COMPARATOR
Intervention: Tumor burden
Number of subjects: 98

Group type: COMPARATOR
Intervention: Percentage of tumor necrosis induced by preoperative chemotherapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Histopathologic subtype (chondroblastic vs osteoblastic)
Number of subjects: 98
Study: 7150174

Group type: EXPERIMENTAL
Intervention: Benactyzine hydrochloride (4.14 mg/70 kg body weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30935742

Group type: EXPERIMENTAL
Intervention: RZV
Number of subjects: 14645

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14645
Study: 28163000

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab
Number of subjects: 1063

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1063
Study: 27440682

Group type: EXPERIMENTAL
Intervention: Ficus carica paste
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 24957569

Group type: EXPERIMENTAL
Intervention: Long-length colonoscope
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Intermediate-length colonoscope
Number of subjects: 1200
Study: 23439606

Group type: EXPERIMENTAL
Intervention: Continuous training program (60%-79% HR max) for 8 weeks, 45-60 minutes, 3 times per week
Number of subjects: 217

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 217
Study: 20041249

Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 350

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 350
Study: 18663319

Group type: EXPERIMENTAL
Intervention: Growth hormone (Genotropin) treatment at a median dose of 0.03 mg/kg/day for a median duration of 10.2 years (range 6.9-11.5)
Number of subjects: 22
Study: 15958097

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 12610038

Group type: EXPERIMENTAL
Intervention: Pramlintide 120 microg BID
Number of subjects: 656

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 656
Study: 10608399

Group type: EXPERIMENTAL
Intervention: MultiHance (gadobenate dimeglumine, Gd‐BOPTA) administered at a dosage of 0.05 mmol/kg during the dynamic phase of contrast enhancement.
Number of subjects: 6
Study: 8719517

Group type: EXPERIMENTAL
Intervention: Engerix-B (EB) 20 micrograms administered IM at 0, 1, 2, and 12 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombivax HB (RHB) 10 micrograms administered IM at 0, 1, and 6 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Engerix-B (EB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recombivax HB (RHB)
Number of subjects: 0
Study: 1837245

Group type: EXPERIMENTAL
Intervention: Niaprazine (1 mg/kg body weight)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 6828120

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 66

Group type: COMPARATOR
Intervention: Chlorothiazide
Number of subjects: 66
Study: 30417225

Group type: COMPARATOR
Intervention: 14-day treatment with 10% carbamide peroxide gel applied for 2 hours a day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 21-day treatment with 10% carbamide peroxide gel applied for 2 hours a day
Number of subjects: 50
Study: 27801539

Group type: EXPERIMENTAL
Intervention: EEA stapler (Covidien)
Number of subjects: 135

Group type: COMPARATOR
Intervention: PPH stapler (Ethicon EndoSurgery)
Number of subjects: 135
Study: 25943679

Group type: EXPERIMENTAL
Intervention: Swimming in 33°C water (HA)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Swimming in 28°C water (CON)
Number of subjects: 8
Study: 24421292

Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 572

Group type: COMPARATOR
Intervention: No confidence in completing forms
Number of subjects: 572

Group type: COMPARATOR
Intervention: Poor self-reported health
Number of subjects: 572
Study: 23127291

Group type: EXPERIMENTAL
Intervention: Intranasal azelastine (AZE; 137 μg/spray)
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate (FP; 50 μg/spray)
Number of subjects: 610
Study: 19200123

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) at 10% concentration and pH 2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) at 5% concentration and pH 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Whey protein isolate (WPI) at varying concentrations (0%, 2.5%, 5%, and 10%) and pH levels (pH 2, 3, and 8)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no WPI)
Number of subjects: 0
Study: 17676256

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups combined
Number of subjects: 26
Study: 15020607

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus trastuzumab
Number of subjects: 247

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Trastuzumab alone or combined with palliative radiotherapy or hormonal therapy
Number of subjects: 247
Study: 11842886

Group type: EXPERIMENTAL
Intervention: Phosphatidylserine (PS) supplementation 300 mg daily for one month
Number of subjects: 0
Study: 9762483

Group type: EXPERIMENTAL
Intervention: Exercise training (walking-jogging)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Lower intensity exercise
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Training more than three times per week or for more than 50 minutes
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 39
Study: 8063359

Group type: EXPERIMENTAL
Intervention: Right nostril pranayama
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alternate nostril pranayama
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Left nostril pranayama
Number of subjects: 48
Study: 3058016

Group type: EXPERIMENTAL
Intervention: HPA-23 (ammonium-21-tungsto-9-antimoniate) at 0.25, 0.5, 1.0, or 2.0 mg/kg intravenously 5 days per week for 8 weeks
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: HPA-23 (ammonium-21-tungsto-9-antimoniate)
Number of subjects: 69
Study: 29859056

Group type: EXPERIMENTAL
Intervention: Under reporting of energy intake at study entry (10‐20 weeks gestation)
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Under reporting of energy intake at 36 weeks gestation
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Adequate reporters at study entry
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Adequate reporters at 36 weeks gestation
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Over reporters at study entry
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Over reporters at 36 weeks gestation
Number of subjects: 945

Group type: EXPERIMENTAL
Intervention: Independent predictors of under reporting of energy intake
Number of subjects: 945
Study: 28391236

Group type: EXPERIMENTAL
Intervention: Unsolicited infectious disease consultant (IDC) counselling
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 500
Study: 25893283

Group type: EXPERIMENTAL
Intervention: Home-based early intervention (8 home visits from community nurses)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Control group (no further intervention)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Home-based early intervention
Number of subjects: 465

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 465
Study: 24649767

Group type: EXPERIMENTAL
Intervention: Vitaprost Plus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lomflox
Number of subjects: 0
Study: 21982727

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times daily)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo tablets (three times daily)
Number of subjects: 120
Study: 18775597

Group type: EXPERIMENTAL
Intervention: Intravaginal metronidazole (2x 1000 mg pessaries 24h apart)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Oral metronidazole (1 x 2000 mg tablets)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Intravaginal metronidazole
Number of subjects: 263

Group type: COMPARATOR
Intervention: Oral metronidazole
Number of subjects: 263
Study: 15932378

Group type: EXPERIMENTAL
Intervention: Impermeable encasings for mattress, pillow and duvet
Number of subjects: 224

Group type: COMPARATOR
Intervention: Nonimpermeable encasings for mattress, pillow and duvet
Number of subjects: 224
Study: 12872393

Group type: EXPERIMENTAL
Intervention: CT positioning scalp circum-needling (SCN) combined with Chinese herbal medicine (Fuyuan mixture)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (Fuyuan mixture only)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups (SCN + FYM and FYM only)
Number of subjects: 89
Study: 10561764

Group type: EXPERIMENTAL
Intervention: Trial off catheter
Number of subjects: 79

Group type: COMPARATOR
Intervention: Trial off catheter 24 hours after admission
Number of subjects: 79
Study: 8885761

Group type: EXPERIMENTAL
Intervention: ephedrine sulfate
Number of subjects: 50

Group type: COMPARATOR
Intervention: normal saline solution
Number of subjects: 50
Study: 1947469

Group type: EXPERIMENTAL
Intervention: High-dose cytosine arabinoside combined with dexamethasone and cisplatinum
Number of subjects: 43

Group type: COMPARATOR
Intervention: Low-dose cytosine arabinoside combined with dexamethasone and cisplatinum
Number of subjects: 43
Study: 6339110

Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 280

Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 280
Study: 31389731

Group type: EXPERIMENTAL
Intervention: Cyclosporin 4 mg/kg/d for 3 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31212940

Group type: EXPERIMENTAL
Intervention: HiEAAs (specially-formulated composition of essential amino acids)
Number of subjects: 0

Group type: COMPARATOR
Intervention: LoEAA (commercially popular protein-based meal replacement beverage)
Number of subjects: 0
Study: 30073679

Group type: EXPERIMENTAL
Intervention: Blinded estimators for within and between person variances
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unblinded approach
Number of subjects: 0
Study: 27193374

Group type: EXPERIMENTAL
Intervention: Allergen-specific immunotherapy (ASIT)
Number of subjects: 205

Group type: COMPARATOR
Intervention: No treatment (untreated group)
Number of subjects: 205
Study: 25037883

Group type: EXPERIMENTAL
Intervention: Subcutaneous growth hormone injection (3 mg/24 h) during exercise (1 hour bicycling with 50 W load)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Subcutaneous growth hormone injection (3 mg/24 h) during supine rest
Number of subjects: 8

Group type: COMPARATOR
Intervention: Continuous subcutaneous growth hormone infusion (3 mg/24 h)
Number of subjects: 8
Study: 23176112

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 109

Group type: COMPARATOR
Intervention: Hyaluronic Acid (HA) injections
Number of subjects: 109
Study: 20103234

Group type: EXPERIMENTAL
Intervention: Intercostal muscle flap and intracostal sutures
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual pericostal sutures
Number of subjects: 120
Study: 16804691

Group type: EXPERIMENTAL
Intervention: Low alcohol dose (two to three drinks equivalent)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: High alcohol dose (four to five drinks equivalent)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (1% volume alcohol as a taste mask)
Number of subjects: 39
Study: 14519178

Group type: EXPERIMENTAL
Intervention: Visual probe task with smoking cues
Number of subjects: 141
Study: 10714423

Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticosteroids (IGC), 250 microg of fluticasone propionate (FP) twice a day for 8 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (control group) for 8 weeks
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticosteroids (IGC)
Number of subjects: 67
Study: 8881621

Group type: EXPERIMENTAL
Intervention: Isoflurane 0.4‐1.2 vol%
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Propofol 3‐5 mg kg‐1 h‐1 i.v.
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Threshold value of SEF 14 Hz
Number of subjects: 49
Study: 1307881

Group type: EXPERIMENTAL
Intervention: Room-temperature thermodilution cardiac output measurements from the right ventricular port
Number of subjects: 37
Study: 3884128

Group type: EXPERIMENTAL
Intervention: Doxorubicin (A) 60 mg/m2
Number of subjects: 104

Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m2 and cyclophosphamide 500 mg/m2 (CA)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Doxorubicin (A) 60 mg/m2 and Doxorubicin 60 mg/m2 and cyclophosphamide 500 mg/m2 (CA)
Number of subjects: 104
Study: 31951279

Group type: EXPERIMENTAL
Intervention: Tocilizumab 162 mg weekly
Number of subjects: 36
Study: 30198644

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inhaled desflurane
Number of subjects: 30
Study: 27575012

Group type: EXPERIMENTAL
Intervention: Therapeutic kinesiology taping (KT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham kinesiology taping (KT)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Shoulder sonography
Number of subjects: 44
Study: 25435604

Group type: EXPERIMENTAL
Intervention: Diabegon (4 gm daily)
Number of subjects: 58
Study: 23059927

Group type: EXPERIMENTAL
Intervention: ASA therapy suspended for seven days before tooth extraction
Number of subjects: 0

Group type: COMPARATOR
Intervention: ASA therapy continued without suspension
Number of subjects: 0
Study: 19926383

Group type: EXPERIMENTAL
Intervention: Self-inflating bag (SI-bag)
Number of subjects: 120

Group type: COMPARATOR
Intervention: T-piece resuscitator
Number of subjects: 120
Study: 18549489

Group type: EXPERIMENTAL
Intervention: Visiting service for older widowed individuals
Number of subjects: 110

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 110
Study: 15817872

Group type: EXPERIMENTAL
Intervention: soy protein isolate enriched with isoflavones (soy‐plus diet)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: soy protein isolate devoid of isoflavones (soy‐minus diet)
Number of subjects: 15

Group type: COMPARATOR
Intervention: casein‐whey protein isolate (control diet)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: soy‐minus diet
Number of subjects: 15
Study: 12091332

Group type: EXPERIMENTAL
Intervention: Intensive-timing induction
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard-timing induction
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: tMDS/tAML
Number of subjects: 24

Group type: COMPARATOR
Intervention: De novo MDS/AML
Number of subjects: 24
Study: 10599711

Group type: EXPERIMENTAL
Intervention: Growth hormone treatment (GH) discontinued after 2 years
Number of subjects: 40
Study: 7805898

Group type: EXPERIMENTAL
Intervention: 5% CO2/90% N2/5% O2 (low oxygen)
Number of subjects: 186

Group type: COMPARATOR
Intervention: 5% CO2/95% air (20% O2) (ambient oxygen)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Low oxygen (mouse embryos)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Ambient oxygen (mouse embryos)
Number of subjects: 186
Study: 1769866

Group type: EXPERIMENTAL
Intervention: Ems brine inhalations (200 ml, 3 times a day for 10 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline solution (200 ml, 3 times a day for 10 days)
Number of subjects: 30
Study: 7140799

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 60 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 180 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ephedrine 25 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31335881

Group type: EXPERIMENTAL
Intervention: TNF inhibitor alone (n = 25)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: TNF inhibitor combined with methotrexate (MTX) (n = 10)
Number of subjects: 51

Group type: COMPARATOR
Intervention: MTX monotherapy (n = 16)
Number of subjects: 51